Research progress in the mechanism of antibody-drug conjugate and its application in the treatment of bladder cancer
10.3969/j.issn.1009-8291.2023.06.001
- VernacularTitle:抗体药物偶联物的作用机制及在膀胱癌中的研究现状
- Author:
Hui ZHAN
1
;
Zhiyong TAN
1
;
Shi FU
1
;
Ning LI
1
;
Jiansong WANG
1
;
Haifeng WANG
1
Author Information
1. Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
- Publication Type:Journal Article
- Keywords:
bladder cancer;
antibody-drug conjugate;
treatment;
prognosis;
targeted drug
- From:
Journal of Modern Urology
2023;28(6):459-463
- CountryChina
- Language:Chinese
-
Abstract:
Bladder cancer (BC) is one of the most common malignancies of the urinary tract. Surgery combined with chemoradiotherapy is the mainstay of treatment, but BC is markedly heterogeneous, leading to unsatisfactory outcomes. Antibody-drug conjugate (ADC), a new type of targeted drug, has achieved remarkable results in the treatment of tumors by coupling a chemical junction with a highly cytotoxic small molecule, which can exert anti-tumor effects while avoiding the impacts on normal cells. To date, several ADCs have been used in the treatment of BC at home and abroad, and play an increasingly important role in the field of BC therapy. This article briefly introduces the mechanism of ADC, the current application of ADC in BC treatment, and the problems and challenges faced, hoping to provide reference for clinical work.
